All News

Duke Appiah, PhD, MPH, discusses maternal health disparities, emphasizing the impact of racial and ethnic factors on pregnancy outcomes for women with cancer.

Data come from patients with stage 3 melanoma enrolled in a phase 3 randomized trial and showed that detection of circulating tumor DNA (ctDNA) prior to adjuvant systemic therapy can predict risk of early recurrence.

As skin cancer rates continue to rise, here are 5 key facts every health care professional should know to improve prevention, early detection, and patient outcomes.

Experts at the Community Oncology Conference discuss innovative patient navigation programs, emphasizing technology's role and the importance of human connection in cancer care.

Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).

Lalan Wilfong, MD, of Thyme Care and Texas Oncology, discusses a session on circulating tumor DNA (ctDNA) and shares insight as chair of the Community Oncology Alliance (COA) Payer Reform Committee.

The findings come from a review of 4 randomized clinical trials, which found that statin use at the start of treatment was associated with improved cancer-related survival, overall survival, and progression-free survival.

Kate Baker, MD, MMHC, medical director of value-based care at Tennessee Oncology, talks about innovations in cancer care highlighted at the Community Oncology Conference.

Self-paying patients can now obtain semaglutide at a lower cost through trusted telehealth providers.

At the 2025 Community Oncology Conference, Nini Wu, MD, Navista, shares how AI can transform community oncology.

Increased levels of human leukocyte antigen G (HLA-G) were associated with inferior overall survival.

Duke Appiah, PhD, MPH, explores racial disparities in maternal health outcomes for pregnant women with cancer, revealing critical insights for informed decision-making.

Experts champion medically integrated care and oncology optimized distribution models as vital strategies to improve outcomes, streamline access, and reduce costs for patients.

Because clinical trials do not mimic the real-world application of multiple myeloma treatments, Ajai Chari, MD, discussed the variety of patient factors clinicians should consider in their practice.

Approximately 1 million Aetna members will need new coverage with the announcement that CVS will be leaving the Affordable Care Act (ACA) individual exchange business next year.

Patients with neovascular age-related macular degeneration (nAMD) experienced improvements in central macular thickness and subretinal and intraretinal fluid after switching.

Experts urge for technology-driven, collaborative solutions as patients shoulder a growing burden of prescription costs.

The results offer some of the first glimpses into real-world findings of the Janus kinase inhibitor in patients with myelofibrosis (MF) and anemia.

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to innovative therapies for all patients.

Infection was a leading cause of death in lower-risk myelodysplastic syndromes (MDS), highlighting the need for vigilant monitoring and preventive strategies.

Key trends and challenges are shaping the next era of advanced therapies, from FDA momentum to broader patient access.

Respiratory diseases made up the hospitalizations in older adults after they were exposed to wildfire smoke.

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older with generalized myasthenia gravis based on data from the ongoing Vivacity-MG3 study.

Mike Fazio, director of value-based care at Navista, Cardinal Health, discusses a trending topic at the 2025 Community Oncology Conference: optimizing oncology care with technology.

Many studies have examined how rheumatoid arthritis therapy affects the risk of metabolic comorbidities.

Results presented on Tuesday at the American Association for Cancer Research annual meeting include data on the combined use of tissue and liquid biopsy, as well as a framework for evaluating multicancer early detection testing.

Oncology leaders from Alliance Cancer Specialists, American Oncology Network, CHI St. Vincent, Memorial Sloan Kettering Cancer Center, and New York Cancer & Blood Specialists discussed the power of collaboration in cancer care, highlighting partnerships that enhance patient outcomes and resource sharing in community practices.

Jon Giles, MD, speaks to the power of personalized medicine and multidisciplinary care to enhance treatment for patients with rheumatoid arthritis (RA).